Conscious Versus General Anesthesia in TAVR

Patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR) can safely undergo the procedure under conscious sedation.

Sedación consciente vs anestesia general en el TAVI

Conscious sedation has been adopted in clinical practice as a natural way of simplifying and conducting the procedure in the least invasive way possible.

Currently, up to 50% of patients undergo TAVR under conscious sedation, but so far there was no randomized evidence on the matter.

SOLVE-TAVI was a multicenter, open-label, 2×2 factorial, randomized trial of 447 patients with aortic stenosis undergoing TAVR, comparing conscious sedation vs. general anesthesia.

The primary efficacy endpoint was a composite powered for equivalence between both strategies for anesthesia. The composite endpoint at 30 days included: all-cause mortality, stroke, infarction, infection requiring antibiotic treatment, and acute kidney injury.


Read also: FFR and iFR Discordance in up to 20% of Cases: Which One Should Inform Our Decisions?


The primary endpoint occurred in 27.2% of patients in the conscious sedation arm vs. 26.4% of patients in the general anesthesia arm (p for equivalence = 0.015).

The rates of individual components also reached significance for equivalence. All-cause mortality was 3.2% for conscious sedation vs. 2.3% for general anesthesia; as regards stroke, 2.4% vs. 2.8%; infarction, 0.5% vs. 0%; infection requiring antibiotic treatment, 21.1% vs. 22%, and acute kidney injury, 9% vs. 9.2%, respectively.

There was a lower need for inotropes or vasopressors in patients who received conscious sedation (62.8% vs. 97.3%).

Conclusion

Conscious sedation had similar results in patients with severe aortic stenosis undergoing transfemoral TAVR compared with general anesthesia. These findings suggest that conscious sedation may be used safely during the procedure.

10-1161-circulationaha-120-046451

Original Title: General versus Local Anesthesia with Conscious Sedation in Transcatheter Aortic Valve Implantation: The Randomized SOLVE-TAVI Trial.

Reference: Holger Thiele et al. Circulation. 2020 Oct 13;142(15):1437-1447. doi: 10.1161/CIRCULATIONAHA.120.046451.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....